Neumora Therapeutics target cut by Guggenheim to $8 from $14
NMRA•Guggenheim cut its target price for Neumora Therapeutics to $8 from $14.
Related News

McEwen grants CFO Perry Ing 3,030 restricted stock units
MUX•

Nasdaq trade halt: news pending at 7:50 p.m.
MOBX•

Meiji Seika Pharma to invest in Arcturus Therapeutics
ARCT•

Light & Wonder grants Jamie Odell 16,413 restricted stock units for consulting services
LNW•

Enovis director Angela S. Lalor reports acquisition of $49,386.14 in common shares
ENOV•